iifl-logo

Medicamen Biotech Ltd Directors Report

Add as a Preferred Source on Google
₹285.9
(-0.52%)
Nov 20, 2026|03:31:45 PM

Medicamen Biotech Ltd Share Price directors Report

Dear Shareholders,

The Board is pleased to present its report on comprehensive review of performance of the Company along with the audited standalone and consolidated financial statements for the financial year ended 31 March 2026.

1. FINANCIAL HIGHLIGHTS

(Amount in Lakhs, except for EPS data)

Particulars Standalone 2025-26 Standalone 2024-25 Consolidated 2025-26 Consolidated 2024-25
Revenue from operations 17,884.58 15,146.33 19,776.97 16,254.72
Other Income 310.43 622.51 311.32 624.39
Total Income 18,195.01 15,768.85 20,088.29 16,879.10
Profit Before Finance Cost, Depreciation and Tax 2,139.10 2,278.19 2,270.03 2,010.22
Finance Cost (278.45) (304.54) (349.74) (315.61)
Depreciation (705.87) (696.21) (721.85) (706.61)
Profit before exceptional items and tax 1,154.78 1,277.44 1,198.44 988.00
Exceptional Items - - - -
Profit Before Tax 1,154.78 1,277.44 1,198.44 988.00
Provision for Tax 254.83 363.95 254.83 363.95
Deferred Tax (40.91) (31.25) -36.03 -31.52
Profit for the year 940.87 944.75 979.64 655.57
Return on Equity 6.94 7.43 7.22 5.16

2. STATEMENT OF AFFAIRS OF THE COMPANY

During 2025-26, the Company strengthened its position in the pharmaceutical industry through sustained focus on business growth, operational excellence and product portfolio enhancement. The Company recorded significant growth in revenue and profitability, driven by strong market demand and effective business strategies.

The Company remained committed to maintaining high standards of quality, regulatory compliance and customer satisfaction while enhancing operational efficiencies through process optimisation, technology adoption and digital initiatives. Continuous efforts were made to strengthen distribution networks, improve internal systems and controls and expand market reach.

The management also focused on workforce development and stakeholder engagement, creating a strong foundation for sustainable growth and long-term value creation.

3. OVERVIEW OF OPERATIONAL AND FINANCIAL PERFORMANCE

On a standalone basis, the Company recorded net revenue of 17,884.58 Lakhs during 2025-26, registering a growth of 18.08% as compared to 15,146.33 Lakhs in 2024-25. Earnings Before Interest, Depreciation and Taxes (EBITDA) stood at 2,139.10 Lakhs in 2025-26 as against 2,278.20 Lakhs in 2024-25. The Company reported a Profit After Tax (PAT) of 940.87 Lakhs during 2025-26 as compared to 944.75 Lakhs in 2024-25.

The consolidated performance of the Company and its subsidiary companies (collectively referred to as "the Group") has been detailed at appropriate places in this Report.

On a consolidated basis, the Group achieved net revenue of 19,776.97 Lakhs during 2025-26, reflecting a growth of 21.66% over the previous years net revenue of 16,254.72 Lakhs. Consolidated EBITDA increased to 2,270.03 Lakhs in 2025-26 from 2,010.22 Lakhs in 2024-25, representing a growth of 12.92%.

The Group reported a consolidated Profit Before Tax (PBT) of 1,198.44 Lakhs in 2025-26 as compared to 988.00 Lakhs in 2024-25. While the consolidated PBT remained largely stable during the year, the Group delivered a strong improvement in profitability at the net level. Consolidated Profit After Tax (PAT) increased to 979.64 Lakhs in 2025-26 from 655.57 Lakhs in 2024-25, registering a growth of 49.43%.

The overall performance reflects the Companys continued focus on operational efficiency, revenue growth and sustainable value creation for its stakeholders.

4. DIVIDEND

During the year under review, the Board of Directors of the Company, at its meeting held on 27 May 2026, the Board recommended a final dividend of ?‚? 1/- per equity share (10%) on face value of ?‚? 10/- each for the financial year ended 31 March 2026. The payment of the final dividend is subject to the approval of the shareholders at the ensuing Annual General Meeting ("AGM") of the Company. Upon approval, the final dividend shall be paid to those shareholders whose names appear in the Register of Members as on the Record Date.

Accordingly, the total dividend for the financial year 2025-26, including the proposed final dividend, aggregates to ?‚? 1/- per equity share (10%) on face value of ?‚? 10/- each, consistent with the dividend of ?‚? 1/- per equity share (10%) paid for the previous financial year 2024-25.

In accordance with the provisions of the Income-tax Act, 2025, dividend distributed by the Company is taxable in the hands of the shareholders and accordingly, the Company shall deduct applicable tax at source at the time of payment of the final dividend.

The Board has recommended the previously mentioned dividend after taking into consideration the financial and non-financial performance of the Company during the financial year under review and in terms of the Companys Dividend Distribution Policy. The policy is available at the website of the Company at:

5. SHARE CAPITAL

5.1 The Particulars of share capital of the Company are as follows:

Particulars Amount (in \u20b9 )
Authorised Share Capital (1,50,00,000 Equity Shares of \u20b9 10 each) 15,00,00,000/-
Issued, Subscribed and Paid-Up Share Capital (1,35,62,815 Equity Shares of \u20b9 10 each) 13,56,28,150/-

5.2 Preferential allotment of securities:

During the financial year 2025-26, the Company undertook a preferential allotment of securities in compliance with the applicable provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("ICDR Regulations").

Pursuant thereto, the Company allotted 8,48,215 (Eight Lakhs Forty-Eight Thousand Two Hundred and Fifteen) Equity Shares of face value ?‚? 10/- (Rupees Ten Only) each, fully paid-up, at an issue price of ?‚? 530/- (Rupees Five Hundred and Thirty Only) per share (including a premium of ?‚? 520/- (Rupees Five Hundred and Twenty) per share).

The Company also issued and allotted 6,50,000 (Six Lakhs and Fifty Thousand Equity Share) Convertible Warrants to Promoter and Non-Promoters category on a preferential basis. Each warrant is convertible into one Equity Share of face value ?‚? 10/- (Rupees Ten Only) each, fully paid-up, within a period of 18 months from the date of allotment, at an issue price of ?‚? 530/- (Rupees Five hundred and thirty only) per warrant (including a premium of ?‚? 520/- (Rupees Five Hundred and Twenty Only) per warrant).

5.3 Details of Utilisation of funds raised through Preferential Issue

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company confirms that the funds raised during the financial year ended 31 March 2026 have been utilized for the purposes for which they were raised, as disclosed in the relevant offer documents and approvals.

There has been no deviation or variation in the utilization of the proceeds from the funds raised by the Company. Accordingly, the Statement of Deviation(s) or Variation(s) reviewed by the Audit Committee and filed with the Stock Exchange(s) during the year indicated Nil deviation and variation.

6. SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES

As at 31 March 2026, the Company had 2 subsidiaries companies. During the financial year 2025-26, there was no addition or cessation of any subsidiary of the Company.

Medicamen Life Sciences Private Limited

Medicamen Life Sciences, a subsidiary established in August 2022, is strengthening Medicamens presence in the Indian pharmaceutical market through a focused portfolio and expanding prescriber network. Its growing presence across leading retail and institutional channels, together with a portfolio focused on Cardiovascular and Diabetes therapies, is driving stronger prescription equity and sustained market momentum.

Opal Pharmaceuticals Pty. Ltd., Australia

A wholly owned subsidiary of the Company, continued its operations during 2025-26. As on 31 March 2026, the subsidiary had total assets of AUD 86,749.08 (50.93 Lakhs) and a net worth of AUD 85,249.09 (50.05 Lakhs). No significant business activities were carried out during the year. The management continues to evaluate opportunities for business development and expansion in the Australian market. Form AOC-1 containing salient features of the financial statements of the subsidiary forms part of this Annual Report.

7. FINANCIAL DETAILS OF SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES

The consolidated financial statements of your Company for the Financial Year 2025-26 have been prepared, in compliance with applicable provisions of the Companies Act, 2013 ("the Act"), the Listing Regulations and applicable Accounting Standards, on the basis of audited financial statements of the Company and its Subsidiaries Companies, as approved by their respective Board of Directors, which form an integral part of the Annual Report.

A report on the performance and financial position of each subsidiary is outlined in Form AOC-1 (Annexure - A), which is attached to the financial statements pursuant to the first proviso to Section 129(3) of the Companies Act, 2013 (the Act) and Rules 5 and 8(1) of the Companies (Accounts) Rules, 2014. The Consolidated Financial Statements presented in this Annual Report include the financial results of the subsidiaries.

The separate financial statements of the subsidiaries are available on the website of the Company and can be accessed under the Subsidiary Annual Reports tab at

8. MATERIAL SUBSIDIARIES

In terms of Regulation 16(1)(c) of the SEBI Listing Regulations, the Company does not have a material subsidiary.

9. CHANGE IN THE NATURE OF THE BUSINESS, IF ANY

During the year under review, the Company expanded its business activities by providing consultancy and product validation services to a foreign company. This activity is in line with the objects of the Company and complements its existing business operations. Accordingly, there was no material change in the nature of the business of the Company during the year under review.

10. MATERIAL CHANGES AND COMMITMENTS, AFFECTING THE FINANCIAL POSITION OF THE COMPANY

Apart from the above, there are no material changes and commitments affecting the financial position of the Company that have occurred between the end of the financial year of the Company to which the financial statements relate and the date of the Report of the Board of Directors.

11. EARNINGS PER SHARE (EPS)

The Basic EPS of the Company stood at 6.94 at standalone level and basic EPS at consolidated level stood at 7.22 for the FY ended 31 March 2026.

12. TRANSFER TO RESERVES

The Board of Directors has not proposed any transfer to the General Reserve for the financial year under review.

13. PUBLIC DEPOSIT

Your Company has not accepted any deposit falling within the meaning of Section 73 or 74 of the Act during the year 2025-26 and as such, no amount on account of principal or interest on deposits from public was outstanding as on the date of the balance sheet.

14. INVESTOR EDUCATION AND PROTECTION FUND (IEPF)

Pursuant to the provisions of Sections 124 and 125 of the Companies Act, 2013 ("the Act") read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended ("IEPF Rules"), dividends remaining unclaimed for a period of seven consecutive years from the date of their transfer to the Unpaid Dividend Account of the Company are required to be transferred to the Investor Education and Protection Fund ("IEPF") established by the Central Government.

Further, the corresponding equity shares on which dividend has remained unclaimed for seven consecutive years or more are also required to be transferred to the demat account of the IEPF Authority. However, this requirement is not applicable where the shares are subject to any specific order of a Court, Tribunal or other statutory authority restraining such transfer.

During the Financial Year 2025-26, the Company transferred the unclaimed dividend pertaining to the Financial Year 2018-19, together with the corresponding equity shares, to the IEPF Authority in accordance with the provisions of the Act and the IEPF Rules.

The details of unclaimed dividend and corresponding equity shares transferred to the IEPF Authority up to 31 March 2026 are as under:

Financial Year Amount of Unclaimed Dividend Transferred ( \u20b9 ) Number of Equity Shares Transferred
2009-10 2,87,303.25 1,34,393
2017-18 3,41,788.00 64,968

Members whose unclaimed dividends and corresponding equity shares have been transferred to the IEPF Authority may claim the same by submitting an online application in Form IEPF-5, available on the website of the IEPF Authority ( ), along with the prescribed documents. The Company extends all necessary assistance to the shareholders in completing the claim process.

The details of unpaid dividends that remain available for claim by the Members as on 31 March 2026 are given below:

Financial Year Date of Declaration Last date for claiming unpaid Dividend
2018-19 25 September 2019 25 October 2026
2019-20 25 September 2020 25 October 2027
2020-21 25 September 2021 25 October 2028
2021-22 27 September 2022 27 October 2029
2022-23 27 September 2023 27 October 2030
2023-24 26 September 2024 26 October 2031
2024-25 26 September 2024 26 October 2032

*Members are requested to claim their unpaid dividends before the respective due dates, failing which the unpaid dividend and the corresponding equity shares relating thereto shall be transferred to the IEPF Authority in accordance with the applicable provisions of the Companies Act, 2013 and the IEPF Rules.

15. PARTICULARS OF INVESTMENTS, LOANS AND GUARANTEES

Your Company has granted loans, provided guarantees, furnished security and made investments in other Companies with the requisite approval and in compliance with the provisions of Section 186 of the Act. The details of such loans, guarantees, securities and investments are provided in note no. 7 to the Standalone Financial Statements forming part of this Annual Report.

16. BOARD OF DIRECTORS AND KEY MANAGEMENT PERSONNEL

i. Board of Directors

The Board of the Company is duly constituted. As on 31 March 2026, your Companys Board had Ten (10) directors comprising One Executive Director, Four Non-Executive Non-Independent Directors and Five Non-Executive Independent Directors including Two Woman Director. The details of Board and Committee composition, tenure of Directors, areas of expertise and other details are available in the Corporate Governance Report, which forms part of this Annual Report. None of the Directors of the Company are disqualified under the provisions of the Act or under the SEBI Listing Regulations.

ii. Board Diversity

The Company has a truly diverse Board that includes and makes good use of diversity in skills, regional and industry experience, background, race, gender, ethnicity, and other distinctions among directors. This diversity is considered in determining the optimum composition of the Board. All Board appointments are made on merit, in the context of skills, experience, independence and knowledge that the Board as a whole requires to be effective.

iii. Declaration by Independent Directors

The Company has received necessary declarations from each Independent Director under Section 149(7) of the Companies Act, 2013, that he/she meets the criteria of independence laid down in Section 149(6) of the Companies Act, 2013 and Regulation 25 of the SEBI Listing Regulations.

iv. Certificate from Company Secretary in practice

The Certificate on Non-Disqualification of Directors pursuant to Regulation 34(3) and Schedule V Para C, Clause 10 (i) of the SEBI Listing Regulations is published in the Annual Report.

v. Registration of Independent Directors in Independent Directors databank

All the Independent Directors of your Company have been registered and are members of Independent Directors Databank maintained by the Indian Institute of Corporate Affairs (IICA).

vi. Changes in the composition of Board of Directors

a. Appointment during the year

Mr Sham Goel (DIN: 02183287) was appointed as an Independent Director with effect from 12 August 2025. Mr Shaival Saurabh (DIN: 01971944) was appointed as an Independent Director with effect from 12 August 2025.

b. Change in designation during the year

During the year under review, the members of the Company at the Annual General Meeting ("AGM") held on 26 September 2025 has approved the change in designation of Mr Ashwani Kumar Sharma (DIN:00325634), as the Whole Time Director of the Company, for a period of 5 (five) years from 12 August 2025 to 11 August 2030, whose office will be liable to determination by retirement by rotation.

c. Term expiration during the year

During the year under review, the second consecutive term of Mr Harish Pande and Mr Arun Kumar as an Independent Directors of the Company expired on 26 February 2026. Consequently, they ceased to hold office as Independent Directors upon completion of their respective tenure in accordance with the provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board places on record its sincere appreciation for the valuable contributions, guidance and support extended by Mr Harish Pande and Mr Arun Kumar during their tenure with the Company.

d. Retirements at the AGM:

In terms of Section 152 of the Act, Mr Suresh Kumar Singh (DIN: 00318015) and Mr Sanjay Bansal (DIN: 00121667) will retire at the ensuing AGM and, being eligible, seek re-appointment. The Board recommends their re-appointment, designated as the Non-Executive Directors and their brief profile has been given in the Notice of the 33rd AGM.

Pursuant to the provisions of Regulation 36 of the SEBI Listing Regulations and Secretarial Standards 2 on General Meetings issued by ICSI, brief particulars of the director proposed to be re-appointed are provided as an annexure to the notice convening the AGM.

vii. Key Managerial Personnel as at the end of FY26:

During the year under review, Mr Ashwani Kumar Sharma (DIN: 00325634) was redesignated from Non-Executive Director to Whole-time Director of the Company and was consequently classified as a Key Managerial Personnel pursuant to the provisions of Section 203 of the Companies Act, 2013. The change was effected upon approval of the Board and Members of the Company, as applicable.

Apart from the above, there were no other changes in the Key Managerial Personnel of the Company during the financial year under review.

S. No Name of the KMP Designation
1 Mr Ashwani Kumar Sharma Whole time director
2 Mr Rajesh Madan Chief Executive Officer
3 Mr Chandan Kumar Chief Financial Officer
4 Ms Parul Choudhary Company Secretary

viii. Policy on Directors Appointment and Remuneration and Other matters

The Companys policy on directors appointment and remuneration and other matters provided in section 178(3) of the Act have been disclosed in the report on Corporate Governance, which forms part of the directors report. The weblink for the same is available at

ix. Criteria for making payments to Non-Executive Directors

Overall remuneration should reflect the size of the Company, complexity of the sector/industry/companys operations and the Companys capacity to pay the remuneration. Independent Directors (ID) and Non-Independent Non-Executive Directors (NED) may be paid commission within regulatory limits. The Nomination and Remuneration Committee will recommend to the Board, the quantum of commission for each Director based on the outcome of the evaluation process which is driven by various factors including attendance and time spent in the Board and committee meetings, individual contributions at the meetings and contributions made by Directors other than in meetings. The criteria for making payments to Non-Executive Directors are also available on the website of the Company -

x. Board Meetings during the year

During 2025-26, Six (6) meetings of the Board were held, the details are disclosed in the report on Corporate Governance, which forms a part of this report. The maximum interval between any two meetings did not exceed 120 days, as prescribed by the Act.

xi. Board Evaluation and Assessment

The Board evaluation serves as an effective mechanism to enhance Board accountability and overall effectiveness. It enables Directors to assess individual as well as collective performance on an ongoing basis.

The evaluation of the Board covers key aspects such as its composition, governance role, effectiveness of functioning, quality of reporting, and adequacy of internal control systems. Committee performance is assessed based on clarity and understanding of their terms of reference, effectiveness of deliberations, quality of information provided, and their overall discharge of responsibilities.

The performance of individual Directors is evaluated on parameters including attendance, contribution to discussions, engagement with fellow Board members, ability to provide guidance on strategic matters, domain knowledge, and commitment towards stakeholders.

All Directors undergo both self-evaluation and peer evaluation.

During 2025-26, the Company conducted a formal Board evaluation process. The evaluation cycle was carried out internally and overseen by the Independent Chairperson of the Nomination and Remuneration Committee.

Further details on the evaluation framework and process are provided in the Corporate Governance section of this Annual Report.

xi. Committees of the Board

As required under the provisions of the Act and the SEBI Listing Regulations, as on 31 March 2026, the Board has the following committees:

?‚? Audit Committee;

?‚? Nomination & Remuneration Committee;

?‚? Risk Management Committee;

?‚? Stakeholders Relationship Committee;

?‚? Internal Complaint Committee

During the year, all recommendations made by the Committees were approved by the Board.

A detailed note on the composition of the various Committees is provided in the report on Corporate Governance, which forms a part of this report.

17. ADEQUACY OF INTERNAL FINANCIAL CONTROLS

Internal financial controls form an integral part of the Companys risk management framework addressing financial and financial reporting risks. They ensure the orderly and efficient conduct of business, including adherence to Company policies, safeguarding of its assets, prevention and detection of fraud, error detection and reporting mechanisms, accuracy and completeness of the accounting records. They aid in the timely preparation of financial statements. The Internal Financial Controls have been documented, digitised, and embedded in the business process. The internal financial controls and risk management systems are periodically tested, reviewed, and evaluated by the management, internal auditors, and the Audit Committee. Based on such evaluation, the Board is of the opinion that the Companys internal financial controls and risk management systems are adequate and operating effectively during the financial year.

18. AUDITORS

i. Statutory Auditor

At the 29th Twenty Ninth AGM held on 27 September 2022, the members had approved the appointment of M/s Rai Qimat & Associates, Chartered Accountants, Gurugram, (Firm Registration No. 013152C) as the Statutory Auditors of the Company to hold office for a period of five years from the conclusion of that AGM till the conclusion of the 34th Thirty-forth) AGM to be held in the year 2027.

ii. Internal Auditor

Pursuant to Section 138 of the Act and the rules made thereunder, M/s Cheena & Associates, Cost Accountants (Firm Registration Number: 00397) are appointed as Internal Auditors of the Company and continue to be the Internal Auditors for FY27 to review various operations of the Company and report their findings to the Audit Committee.

iii. Cost Auditor

Pursuant to the provisions of Section 148 of the Companies Act, 2013 and as per the Companies (Cost Records and Audit) Rules, 2014 and amendments thereof, the Board at its meeting held on 27 May 2026, approved the appointment of M/s SPB & Co., Cost Auditors (Firm Registration No. 102586) as Cost Auditors of the Company for audit of cost accounting records for 2026-27.

M/s SPB & Co., Cost Auditors (Firm Registration No. 102586), Cost Accountants, have confirmed their independent status and their non-disqualification under section 141 of the Companies Act, 2013.

A proposal for ratification of remuneration of the Cost Auditor for 2026-27 will be placed before the shareholders for consideration in the ensuing AGM of the Company.

iv. Secretarial Auditors

At the 32nd (Thirty-second) AGM held on 26 September 2025, the members had approved the appointment of M/s AMJ & Associates, Company Secretary, a peer-reviewed Sole Proprietorship firm of Practicing Company Secretaries (Peer Review Certification No. 1640/2021) as the Secretarial Auditors of the Company at the ensuing AGM for a term of 5 (five) consecutive years commencing from the conclusion of 32nd (Thirty-second) Annual General Meeting until the conclusion of 37th (Thirty-seventh) Annual General Meeting to be held in the year 2030.

19. AUDITORS REPORT AND SECRETARIAL AUDITORS REPORT

Auditors Report:

The Auditors Report for 2025-26 of M/s Rai Qimat & Associates on the Financial Statements of the Company for 2025-26 does not contain any qualification, reservation or adverse remark. The Report is enclosed with the financial statements in this Annual Report.

Secretarial Auditors Report:

The Company has undertaken an audit for the 2025-26 as required under the Act and the SEBI Listing Regulations. As per Section 134 (3) (f) explanations or comments by the Board on every qualification, reservation or adverse remark or disclaimer made by the company secretary in practice in his secretarial audit report; The Secretarial Audit Report of M/s AMJ & Associates, Practicing Company Secretaries (CP no 5629) for the financial year ended 31 March 2026 is enclosed to this report. Kindly refer to Annexure B.

Instances of fraud reported by the Auditors:

During the 2025-26, the statutory auditors and the secretarial auditor have not reported any instances of frauds committed in the Company by its Officers or Employees under section 143(12) of the Act to the Central Government or the Audit Committee under section 143(12) of the Companies Act.

Annual Secretarial Compliance Report:

The Annual Secretarial Compliance Report for the Financial Year 2025-26 for all applicable compliance as per the Securities and Exchange Board of India Regulations and Circulars/Guidelines issued thereunder has been duly obtained by the Company.

The Annual Secretarial Compliance Report issued by M/s AMJ & Associates, Practicing Company Secretary (CP No.5629) will be submitted to the Stock Exchanges within 60 days of the end of the Financial Year.

20. WHISTLE BLOWER POLICY AND VIGIL MECHANISM

In Compliance with the provisions of Section 177 of the Act read with rules framed thereunder and Regulation 22 of the Listing Regulations, as amended, the Company has established a Whistle Blower Policy and Vigil Mechanism for its Directors, Employees and Other Stakeholders.

The mechanism provides a structured platform for reporting concerns relating to breach of code of conduct, financial irregularities, illegal or unethical practices, unethical behaviour, actual or suspected fraud. Adequate safeguards are built into the framework to protect whistle-blowers against victimisation, and in appropriate cases, direct access is provided to the Chairman of the Audit Committee.

The policy ensures that strict confidentiality is maintained whilst dealing with concerns and also that no discrimination is made against any person. The Whistle Blower Policy and Vigil Mechanism may be accessed on the Companys website at

21. CREDIT RATINGS

There were no changes in the credit ratings of the Company during the year under review. As on 31 March 2026, the Company had a short-term credit rating of CRISIL A3 and a long-term rating of CRISIL BBB-/Stable by CRISIL Limited for bank loan facilities aggregating to 42 Crores.

22. RELATED PARTY TRANSACTIONS

All contracts, arrangements and transactions entered by the Company with related parties during 2025-26 were in the ordinary course of business and on an arms length basis. Details of the related party transactions as per Ind AS24 have been provided in note no. 2.26 of the notes to standalone financial statements for the year ended 31 March 2026.

During the year, the Company did not enter into any transaction, contract or arrangement with related parties, that could be considered material in accordance with the provisions of the Act or the SEBI Listing Regulations and the Companys Policy on Related Party Transactions ("RPT Policy").

The information on transactions with related parties pursuant to Section 134(3) (h) of the Act read with Rule 8(2) of the Companies (Accounts) Rules, 2014 are given in "Annexure C" in Form No. AOC-2 and the same forms part of this report.

The Policy on Related Party Transactions was amended during the year to align the same with the statutory requirements. The updated RPT policy of the Company is available on the Companys website at

In terms of Regulation 23 of the SEBI Listing Regulations, the Company submits details of RPTs on a consolidated basis, as per the format specified in the relevant accounting standards to the stock exchanges on a half-yearly basis.

23. RISK MANAGEMENT

The Company has in place a comprehensive Risk Management framework, which is embedded into its business processes and forms an integral part of its governance practices. The risk management process involves identification, assessment, evaluation, mitigation and continuous monitoring of risks across the organisation.

The Board has constituted a Risk Management Committee in accordance with the applicable provisions of the SEBI Listing Regulations, to oversee the implementation of the risk management framework. In addition, an internal Risk Management Committee, comprising cross-functional senior management members, supports the Board-level Committee in the identification, assessment, mitigation and continuous monitoring of risks.

Further details on the Risk Management framework, key risks, and mitigation measures are provided in the Management Discussion and Analysis (MD&A) Report. Additional information on the Risk Management Committee of the Board is available in the Corporate Governance section of this Annual Report.

24. MANAGEMENT DISCUSSION & ANALYSIS

The Management Discussion and Analysis Report on the financial performance and results of operations of the Company, as required under the Listing Regulations is provided in a separate section and forms an integral part of this Annual Report. The Report, inter-alia, provides an overview of the industry structure, key economic developments, the Companys business performance and operational highlights, its state of affairs, key risks and concerns and significant developments during the financial year under review.

25. DIRECTORS RESPONSIBILITY STATEMENT

In terms of Sections 134(3)(c) and 134(5) of the Act, the Directors, to the best of their knowledge and ability, confirm that for the year ended 31 March 2026:

(i) in the preparation of the annual accounts, the applicable accounting standards have been followed and that there are no material departures;

(ii) they have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that period;

(iii) they have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

(iv) they have prepared the annual accounts on a going concern basis;

(v) they have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and

(vi) they have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

26. GOVERNANCE, COMPLIANCE AND ETHICS

The Governance, Corporate Secretarial and Legal functions of the Company ensure maintenance of good governance within the organisation. They assist the business in functioning smoothly by ensuring compliance and providing strategic business partnership in the areas including legislative expertise, corporate restructuring, regulatory changes and governance.

The Company has also adopted the governance guidelines on Board effectiveness to fulfil its responsibility towards its stakeholders. With a view to uphold human rights as an integral aspect of doing business, being committed to respect and protect human rights and remediate adverse human rights impact resulting from or caused by the Companys businesses, the Board has been adopted Business Responsibility Policy.

In compliance with the SEBI Listing Regulations, the Corporate Governance Report and the Auditors Certificate form part of this Annual Report.

27. ANNUAL RETURN

Pursuant to Section 92(3) of the Act and Rule 12 of the Companies (Management and Administration) Rules, 2014 read with Section 134(3)(a) of the Act, the Annual Return in Form MGT-7 as on 31 March 2026 is available on the Companys website at

28. BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT

In pursuance of Regulation 34 of the SEBI Listing Regulations, the Business Responsibility and Sustainability Report describing the initiatives taken by the Company from an environmental, social and governance perspective is enclosed with this report. Kindly refer to Annexure - D. The weblink for the same is available at

29. PARTICULARS RELATING TO THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013 (POSH)

The Company has complied with the provisions relating to the constitution of the Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

The Company is committed to providing a safe and inclusive work environment and has in place a POSH Policy. Regular awareness and sensitisation programmes were conducted during the year for employees across all locations, including induction sessions for new employees.

The Internal Complaints Committee reviews the policy implementation periodically and ensures adequate awareness across the organisation.

List of Initiatives under POSH for FY26:

?‚? POSH Committee connects every quarter to ensure the complaints (if any) registered are duly discussed with an improved approach on building awareness.

?‚? POSH Committee has been nominated for training in various forums

?‚? Conducted PoSH awareness sessions during the year, for all associates (white-collar, blue-collar and contract employees) in all locations.

The following is the summary of the complaints received and disposed of during FY26:

(a) Number of complaints received: NIL (b) Number of complaints disposed: NIL (c) Number of complaints pending as on end of FY26: Nil

30. SECRETARIAL STANDARDS

The Company has devised proper systems to ensure compliance with the provisions of all applicable Secretarial Standards issued by the Institute of Company Secretaries of India and that such systems are adequate and operating effectively.

31. PERFORMANCE EVALUATION

The evaluation of all the Directors, Committees, Chairperson of the Board, and the Board as a whole, was conducted based on the criteria and framework adopted by the Committee.

The Board sought the feedback of Directors on various parameters including:

i. Degree of fulfilment of key responsibilities towards stakeholders (by way of monitoring corporate governance practices, participation in the long-term strategic planning, etc.)

ii. Structure, composition and role clarity of the Board and Committees;

iii. Extent of co-ordination and cohesiveness between the Board and its Committees;

iv. Effectiveness of the deliberations and process management;

v. Board/Committee culture and dynamics; and

vi. Quality of relationship between Board Members and the Management.

In a separate meeting of the Independent Directors, the performance of the Non-Independent Directors, the Board as a whole and Chairperson of the Company were evaluated taking into account the views of Executive Directors and other Non-Executive Directors. The NRC reviewed the performance of the individual directors and the Board as a whole.

In the Board

32. SIG NIFICANT AND MATERIAL ORDERS

THE REGULATORS OR COURTS

The re are no significant, material orders the Regulators or Courts, which would impact the going concern status of the Company and its future operations.

33. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The information on conservation of energy, absorption and foreign exchange earnings and outgo stipulated under Section 134(3) (m) of the Act read with Rule 8 of the Companies (Accounts) Rules, 2014 be attached as " Annexure E " which forms part of this Report.

34. P ARTICULARS OF EMPLOYEES AND REMUNERATION

In terms of the provisions of Section 197(12) Companies Act, 2013 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, disclosures pertaining to remuneration and other details are provided in the " Annexure F " to this Report.

35. CORPORATE SOCIAL RESPONSIBILITY

The annual report on Corporate Social ( CSR ) containing details of CSR Policy, composition of the CSR Committee, CSR projects undertaken and web-link thereto on the website of the Company, as required under Companies (Corporate Social Responsibility Policy) Rules, 2014, is set out in Annexure G to this

Report. For other details regarding the CSR Committee, please refer to the Report on Corporate Governance, which is a part of this Annual Report.

During the Financial Year 2025-26, the Company was required to spend a statutory CSR amount of Rs. 31,33,024 in terms of Section 135 of the Companies Act, 2013. The Company incurred an amount of Rs. 25,20,000 towards various community and social welfare projects during the Financial Year. Accordingly, an unspent amount of Rs. 6,13,024.03 remained at the close of the Financial Year 2025-26. Since the said unspent amount did not relate to any Ongoing Project, the Company shall transfer the unspent CSR amount of Rs. 6,13,024.03 to the fund(s) specified in Schedule VII to the Companies Act, 2013, within the prescribed time limit and in accordance with the applicable provisions of Section 135 of the Companies Act, 2013.

BY 36. INSURANCE

All properties and insurable interests of the Company by including buildings, plant and machinery and stocks have been fully insured.

37. HUM AN RESOURCES

The Company believes that competent and committed human resources are important to achieve success in the organisation. In line with this philosophy, utmost care is being exercised to attract quality resources and suitable training is imparted on various skill-sets and behavior. Various initiatives were undertaken to enhance the competitive spirit and encourage bonding teamwork among the employees to achieve the targeted growth in the performance of the Company.

38. DISCL OSURE RELATED TO INSOLVENCY AND

BANKRUPTCY the No application has been filed under the Insolvency and Bankruptcy Code. Therefore, the requirement to disclose any applications filed or proceedings pending under the Insolvency and Bankruptcy Code, 2016 during the year, along with their status at the close of the financial year, is not applicable.

39. DISCL OSURE RELATED TO ONE-TIME SETTLEMENT

The re was no instance of one-time settlement with any Bank or Financial Institution.

40. GREEN INITIATIVE

Y our Directors would like to draw your attention to section 20 of the Companies act, 2013 read with the Companies (Management and administration) Rules, 2014 as may be amended from time to time which permit the paperless compliances and also service of notice/documents (including annual report) through electronic mode to its shareholders.

Y our Directors hereby once again appeal to all those members who have not registered their e mail address so far are requested to register their email address in respect of electronic holding with their concerned Depository participants and /or with the Company.

41. CODE OF CONDUCT

The Board of Directors has approved a Code of Conduct which is applicable to the Members of the Board and all employees in the course of day-to-day business operations of the company. The Company

believes in " Zero Tolerance " against bribery, corruption and unethical dealings / behaviours of any form and the Board has laid down the directives to counter such acts. The Code has been posted on the Company s website www.medicamen.com. The Code lays down the standard procedure of business conduct which is expected to be followed by the Directors and the designated employees in their business dealings and in particular on matters relating to integrity in the work place, in business practices and in dealing with stakeholders.

42. ACKNOWLEDGEMENT

The Directors appreciate and value the contribution, dedication, hard work and commitment made by all the employees and acknowledges the support extended by them during these challenging times.

The Directors would also like to place on record their appreciation for the continued co-operation and support received by the Company during the year from bankers, financial institutions, government authorities, farming community, business partners, shareholders, customers and other stakeholders. The Directors look forward to continuance of the supportive relations and assistance in the future.

By the Order of the Board
Medicamen Biotech Limited
Sd/-
Rahul Bishnoi
Place: New Delhi Chairman
Date: 14 August 2026 DIN-00317960

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited. All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.